Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
CELLTRION, INC. |
End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 163,100.00 KRW | +0.12% | -2.92% | +1.62% | |
| Nov. 14 | Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Nov. 09 | Celltrion, Inc. authorizes a Buyback Plan. | CI |
| Sales 2023 * | 2,448 2 | Sales 2024 * | 2,859 2 | Capitalization | 22,640 B 17.50 B |
|---|---|---|---|---|---|
| Net income 2023 * | 653 1 | Net income 2024 * | 773 1 | EV / Sales 2023 * | 9,08x |
| Net cash position 2023 * | 423 0 | Net cash position 2024 * | 859 1 | EV / Sales 2024 * | 7,62x |
| P/E ratio 2023 * | 36,9x | P/E ratio 2024 * | 34,5x | Employees | 2,034 |
| Yield 2023 * | 0,26% | Yield 2024 * | 0,23% | Free-Float | 73.92% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +0.12% | ||
| 1 week | -2.92% | ||
| Current month | +0.12% | ||
| 1 month | +8.88% | ||
| 3 months | +13.34% | ||
| 6 months | -5.99% | ||
| Current year | +1.62% |
1 week
160 600.00
167 800.00
1 month
151 500.00173 200.00
Current year
131 000.00184 100.00
1 year
131 000.00184 100.00
3 years
131 000.00372 915.00
5 years
121 026.29372 915.00
10 years
26 617.76372 915.00
| Managers | Title | Age | Since |
|---|---|---|---|
Wu-Sung Ki
CEO | Chief Executive Officer | 62 | 2007 |
Ho-Seop Lee
DFI | Director of Finance/CFO | 48 | - |
Jung-Jin Seo
CHM | Chairman | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jung-Jin Seo
CHM | Chairman | 66 | - |
Jae-Sik Lee
BRD | Director/Board Member | 65 | - |
Dong-Il Kim
BRD | Director/Board Member | 65 | 2008 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 163,100.00 | +0.12% | 239,925 |
| 23-11-30 | 162,900.00 | +0.74% | 370,771 |
| 23-11-29 | 161,700.00 | -2.00% | 296,616 |
| 23-11-28 | 165,000.00 | +1.35% | 301,166 |
| 23-11-27 | 162,800.00 | -3.10% | 457,392 |
End-of-day quote Korea Stock Exchange, December 30, 2023
More quotes
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical Pharmaceutical segment is involved in the manufacturing and sale of therapeutic drugs for liver disease under the name of Godex, as well as the treatment of autoimmune diseases under the name of Remsima. The Other segment manufactures and sells other generic drugs. The Company distributes its products within the domestic market and to overseas markets.
Calendar
2024-02-19
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
163,100.00KRW
Average target price
216,944.44KRW
Spread / Average Target
+33.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.62% | 17 412 M $ | |
| +65.53% | 40 132 M $ | |
| +5.87% | 39 586 M $ | |
| -55.56% | 30 438 M $ | |
| -26.11% | 28 571 M $ | |
| +38.66% | 22 175 M $ | |
| -27.87% | 21 511 M $ | |
| -13.43% | 11 313 M $ | |
| -7.44% | 10 346 M $ | |
| -22.08% | 10 212 M $ |
